Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Status unconfirmed · Phase 2

Conditions studied: Chemotherapy Induced Nausea and Vomiting

In brief

The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines

Key facts

Study ID

NCT06065722

Run by

Simon Williamson Clinic

People needed

100

Starts

2023-09-09

Expected to finish

2023-12-31

Last updated by the study team

2023-10-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• CHEMOTHERAPY NAIIVE
• patient receiving moderately or highly emetogenic chemotherapy
• lung cancer
• breast cancer

You may not qualify if…

• PRIOR CHEMOTHERAPY for any cancer
• nausea or vomiting 24 hours prior to study entry

Where it is running

• Rudolph M Navari — Mount Olive, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.